JPH10500978A - ｐ５３タンパク質の調節による腫瘍の治療方法 - Google Patents

ｐ５３タンパク質の調節による腫瘍の治療方法

Info

Publication number: JPH10500978A
Authority: JP; Japan
Prior art keywords: protein; nucleic acid; calpain; vector; activity
Prior art date: 1994-05-31
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP8500420A

Other languages

English (en)

Japanese (ja)

Inventor

ジヤン−マリーブランシヤール，

セルジユカリヨ，

マルクピエシヤクジク，

Original Assignee

ローン−プーラン・ロレ・ソシエテ・アノニム

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-05-31

Filing date

1995-05-22

Publication date

1998-01-27

1995-05-22 Application filed by ローン−プーラン・ロレ・ソシエテ・アノニム filed Critical ローン−プーラン・ロレ・ソシエテ・アノニム

1998-01-27 Publication of JPH10500978A publication Critical patent/JPH10500978A/ja

Status Pending legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims abstract description 25
206010028980 Neoplasm Diseases 0.000 title claims abstract description 24
108010032088 Calpain Proteins 0.000 claims abstract description 37
102000007590 Calpain Human genes 0.000 claims abstract description 37
230000000694 effects Effects 0.000 claims abstract description 30
150000001875 compounds Chemical class 0.000 claims abstract description 24
108090000623 proteins and genes Proteins 0.000 claims description 42
241000701161 unidentified adenovirus Species 0.000 claims description 41
150000007523 nucleic acids Chemical group 0.000 claims description 32
230000015556 catabolic process Effects 0.000 claims description 28
238000006731 degradation reaction Methods 0.000 claims description 28
102000004169 proteins and genes Human genes 0.000 claims description 26
239000013598 vector Substances 0.000 claims description 26
102100035037 Calpastatin Human genes 0.000 claims description 22
108010044208 calpastatin Proteins 0.000 claims description 22
ZXJCOYBPXOBJMU-HSQGJUDPSA-N calpastatin peptide Ac 184-210 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCSC)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(O)=O)NC(C)=O)[C@@H](C)O)C1=CC=C(O)C=C1 ZXJCOYBPXOBJMU-HSQGJUDPSA-N 0.000 claims description 22
108090000765 processed proteins & peptides Proteins 0.000 claims description 19
108020004707 nucleic acids Proteins 0.000 claims description 18
102000039446 nucleic acids Human genes 0.000 claims description 18
239000003112 inhibitor Substances 0.000 claims description 17
108091028043 Nucleic acid sequence Proteins 0.000 claims description 14
102000004196 processed proteins & peptides Human genes 0.000 claims description 10
239000000203 mixture Substances 0.000 claims description 9
229920001184 polypeptide Polymers 0.000 claims description 9
241001430294 unidentified retrovirus Species 0.000 claims description 8
239000008194 pharmaceutical composition Substances 0.000 claims description 7
230000000593 degrading effect Effects 0.000 claims description 5
238000002360 preparation method Methods 0.000 claims description 4
239000013603 viral vector Substances 0.000 claims description 4
241000702421 Dependoparvovirus Species 0.000 claims description 3
150000002632 lipids Chemical class 0.000 claims description 3
239000002502 liposome Substances 0.000 claims description 3
241001634120 Adeno-associated virus - 5 Species 0.000 claims description 2
230000006698 induction Effects 0.000 claims description 2
239000003795 chemical substances by application Substances 0.000 claims 1
239000003814 drug Substances 0.000 claims 1
229940079593 drug Drugs 0.000 claims 1
230000001105 regulatory effect Effects 0.000 abstract description 5
210000004027 cell Anatomy 0.000 description 25
241000700605 Viruses Species 0.000 description 17
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 16
229910052791 calcium Inorganic materials 0.000 description 16
239000011575 calcium Substances 0.000 description 16
230000002950 deficient Effects 0.000 description 15
239000013612 plasmid Substances 0.000 description 15
230000014509 gene expression Effects 0.000 description 13
241000282414 Homo sapiens Species 0.000 description 10
239000012634 fragment Substances 0.000 description 10
108020004414 DNA Proteins 0.000 description 9
210000004881 tumor cell Anatomy 0.000 description 9
230000001086 cytosolic effect Effects 0.000 description 8
238000002474 experimental method Methods 0.000 description 8
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 7
239000000284 extract Substances 0.000 description 7
238000002744 homologous recombination Methods 0.000 description 7
230000006801 homologous recombination Effects 0.000 description 7
239000006166 lysate Substances 0.000 description 7
238000007792 addition Methods 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 6
210000004748 cultured cell Anatomy 0.000 description 6
230000006870 function Effects 0.000 description 6
238000012986 modification Methods 0.000 description 6
230000004048 modification Effects 0.000 description 6
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 6
210000001995 reticulocyte Anatomy 0.000 description 6
108700020796 Oncogene Proteins 0.000 description 5
230000033228 biological regulation Effects 0.000 description 5
238000010276 construction Methods 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
230000002797 proteolythic effect Effects 0.000 description 5
239000000126 substance Substances 0.000 description 5
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
241001135569 Human adenovirus 5 Species 0.000 description 4
241000699666 Mus <mouse, genus> Species 0.000 description 4
241000283973 Oryctolagus cuniculus Species 0.000 description 4
102000035195 Peptidases Human genes 0.000 description 4
108091005804 Peptidases Proteins 0.000 description 4
238000013459 approach Methods 0.000 description 4
238000012217 deletion Methods 0.000 description 4
230000037430 deletion Effects 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
230000003834 intracellular effect Effects 0.000 description 4
108010011767 m-calpain Proteins 0.000 description 4
108700028369 Alleles Proteins 0.000 description 3
208000003322 Coinfection Diseases 0.000 description 3
241000588724 Escherichia coli Species 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
241000714474 Rous sarcoma virus Species 0.000 description 3
230000006907 apoptotic process Effects 0.000 description 3
239000000872 buffer Substances 0.000 description 3
108010079785 calpain inhibitors Proteins 0.000 description 3
238000012761 co-transfection Methods 0.000 description 3
230000002068 genetic effect Effects 0.000 description 3
230000002246 oncogenic effect Effects 0.000 description 3
238000012552 review Methods 0.000 description 3
239000000243 solution Substances 0.000 description 3
239000000758 substrate Substances 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
238000012546 transfer Methods 0.000 description 3
230000003612 virological effect Effects 0.000 description 3
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
229920000936 Agarose Polymers 0.000 description 2
108010039627 Aprotinin Proteins 0.000 description 2
241000282472 Canis lupus familiaris Species 0.000 description 2
102000004594 DNA Polymerase I Human genes 0.000 description 2
108010017826 DNA Polymerase I Proteins 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
241000701533 Escherichia virus T4 Species 0.000 description 2
GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 2
102000043276 Oncogene Human genes 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
102000044209 Tumor Suppressor Genes Human genes 0.000 description 2
108700025716 Tumor Suppressor Genes Proteins 0.000 description 2
108700005077 Viral Genes Proteins 0.000 description 2
229960004405 aprotinin Drugs 0.000 description 2
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
239000002738 chelating agent Substances 0.000 description 2
YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 2
210000001072 colon Anatomy 0.000 description 2
208000029742 colonic neoplasm Diseases 0.000 description 2
238000000432 density-gradient centrifugation Methods 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
230000002708 enhancing effect Effects 0.000 description 2
239000002532 enzyme inhibitor Substances 0.000 description 2
238000000605 extraction Methods 0.000 description 2
238000001502 gel electrophoresis Methods 0.000 description 2
238000010353 genetic engineering Methods 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 2
108010052968 leupeptin Proteins 0.000 description 2
208000037841 lung tumor Diseases 0.000 description 2
238000001823 molecular biology technique Methods 0.000 description 2
230000035772 mutation Effects 0.000 description 2
239000002773 nucleotide Substances 0.000 description 2
125000003729 nucleotide group Chemical group 0.000 description 2
210000004940 nucleus Anatomy 0.000 description 2
230000007170 pathology Effects 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
230000008569 process Effects 0.000 description 2
239000000047 product Substances 0.000 description 2
238000000746 purification Methods 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
230000010076 replication Effects 0.000 description 2
239000008223 sterile water Substances 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
230000000381 tumorigenic effect Effects 0.000 description 2
241001529453 unidentified herpesvirus Species 0.000 description 2
230000029812 viral genome replication Effects 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
101100451260 Arabidopsis thaliana HMGS gene Proteins 0.000 description 1
241000271566 Aves Species 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
101000867691 Bos taurus Calpain-2 catalytic subunit Proteins 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
229940121926 Calpain inhibitor Drugs 0.000 description 1
241000701157 Canine mastadenovirus A Species 0.000 description 1
101150044789 Cap gene Proteins 0.000 description 1
108090000565 Capsid Proteins Proteins 0.000 description 1
102100038909 Caveolin-2 Human genes 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
102100023321 Ceruloplasmin Human genes 0.000 description 1
102000012410 DNA Ligases Human genes 0.000 description 1
108010061982 DNA Ligases Proteins 0.000 description 1
241000450599 DNA viruses Species 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
101150029662 E1 gene Proteins 0.000 description 1
241001524679 Escherichia virus M13 Species 0.000 description 1
206010061968 Gastric neoplasm Diseases 0.000 description 1
235000010469 Glycine max Nutrition 0.000 description 1
244000068988 Glycine max Species 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000740981 Homo sapiens Caveolin-2 Proteins 0.000 description 1
108090000144 Human Proteins Proteins 0.000 description 1
102000003839 Human Proteins Human genes 0.000 description 1
241000701109 Human adenovirus 2 Species 0.000 description 1
108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
108010021466 Mutant Proteins Proteins 0.000 description 1
102000008300 Mutant Proteins Human genes 0.000 description 1
108091061960 Naked DNA Proteins 0.000 description 1
206010061309 Neoplasm progression Diseases 0.000 description 1
102000007999 Nuclear Proteins Human genes 0.000 description 1
108010089610 Nuclear Proteins Proteins 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
241001494479 Pecora Species 0.000 description 1
239000004365 Protease Substances 0.000 description 1
208000015634 Rectal Neoplasms Diseases 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
241000282887 Suidae Species 0.000 description 1
108010022394 Threonine synthase Proteins 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
101710162629 Trypsin inhibitor Proteins 0.000 description 1
229940122618 Trypsin inhibitor Drugs 0.000 description 1
108090000848 Ubiquitin Proteins 0.000 description 1
102000044159 Ubiquitin Human genes 0.000 description 1
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000003321 amplification Effects 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
230000001028 anti-proliverative effect Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
230000002622 anti-tumorigenesis Effects 0.000 description 1
239000000427 antigen Substances 0.000 description 1
230000030741 antigen processing and presentation Effects 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
238000003782 apoptosis assay Methods 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
102000005936 beta-Galactosidase Human genes 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
ZSJHIZJESFFXAU-UHFFFAOYSA-N boric acid;phosphoric acid Chemical compound OB(O)O.OP(O)(O)=O ZSJHIZJESFFXAU-UHFFFAOYSA-N 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
230000006652 catabolic pathway Effects 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000032823 cell division Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
108091092356 cellular DNA Proteins 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000013522 chelant Substances 0.000 description 1
230000009920 chelation Effects 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000012937 correction Methods 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
239000007857 degradation product Substances 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
230000029087 digestion Effects 0.000 description 1
102000004419 dihydrofolate reductase Human genes 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
-1 etc.) Chemical compound 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
230000012010 growth Effects 0.000 description 1
210000002443 helper t lymphocyte Anatomy 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
239000002609 medium Substances 0.000 description 1
230000011278 mitosis Effects 0.000 description 1
239000011259 mixed solution Substances 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
208000008813 mosaic variegated aneuploidy syndrome Diseases 0.000 description 1
108010068164 mu-calpain Proteins 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
231100000219 mutagenic Toxicity 0.000 description 1
230000003505 mutagenic effect Effects 0.000 description 1
208000025402 neoplasm of esophagus Diseases 0.000 description 1
210000000633 nuclear envelope Anatomy 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
231100000590 oncogenic Toxicity 0.000 description 1
108091008819 oncoproteins Proteins 0.000 description 1
102000027450 oncoproteins Human genes 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000035515 penetration Effects 0.000 description 1
230000004481 post-translational protein modification Effects 0.000 description 1
SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 1
230000005522 programmed cell death Effects 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
238000000751 protein extraction Methods 0.000 description 1
239000012460 protein solution Substances 0.000 description 1
230000006798 recombination Effects 0.000 description 1
238000005215 recombination Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
238000001890 transfection Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
239000002753 trypsin inhibitor Substances 0.000 description 1
230000005751 tumor progression Effects 0.000 description 1
230000037455 tumor specific immune response Effects 0.000 description 1
231100000588 tumorigenic Toxicity 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
230000006648 viral gene expression Effects 0.000 description 1
210000002845 virion Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Biophysics (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Epidemiology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

JP8500420A 1994-05-31 1995-05-22 ｐ５３タンパク質の調節による腫瘍の治療方法 Pending JPH10500978A (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
FR94/06583		1994-05-31
FR9406583A FR2720277B1 (fr)	1994-05-31	1994-05-31	Méthode de traitement des cancers par régulation de la protéine P53.
PCT/FR1995/000670 WO1995033060A1 (fr)	1994-05-31	1995-05-22	Methode de traitement des cancers par regulation de la proteine p53

Publications (1)

Publication Number	Publication Date
JPH10500978A true JPH10500978A (ja)	1998-01-27

Family

ID=9463670

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP8500420A Pending JPH10500978A (ja)	1994-05-31	1995-05-22	ｐ５３タンパク質の調節による腫瘍の治療方法

Country Status (8)

Country	Link
EP (1)	EP0763121A1 (fi)
JP (1)	JPH10500978A (fi)
AU (1)	AU714209B2 (fi)
CA (1)	CA2190293C (fi)
FI (1)	FI120501B (fi)
FR (1)	FR2720277B1 (fi)
NO (1)	NO321411B1 (fi)
WO (1)	WO1995033060A1 (fi)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19518488C1 (de) *	1995-05-19	1996-10-10	Progen Biotechnik Gmbh	Autoantigen, geeignet zur Feststellung einer Thromboseneigung
EP0799892A3 (en) *	1996-04-05	1998-08-12	Takeda Chemical Industries, Ltd.	Calpain, its production and use
US6232454B1 (en)	1998-02-27	2001-05-15	Incyte Genomics, Inc.	Human proteinase molecules
AU2344100A (en) *	1998-11-18	2000-06-05	Canji, Inc.	Viral vectors with late transgene expression
AU2001247922A1 (en) *	2000-03-31	2001-10-15	Parker Hughes Institute	Calpain inhibitors in cancer treatment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH0753665B2 (ja) *	1984-04-20	1995-06-07	財団法人癌研究会	抗転移剤
US5340922B1 (en) *	1988-05-31	1999-11-02	Mclean Hospital Corp	Neural calcium-activated neutral proteinase inhibitors
EP0395309B1 (en) *	1989-04-28	1995-12-27	Takara Shuzo Co. Ltd.	Human calpastatin-like polypeptide
JPH0641067A (ja) *	1992-04-20	1994-02-15	Kitasato Inst:The	新規カルパイン阻害物質ｋｐ−１２４１及びその製造法
EP0580161A1 (en) *	1992-07-22	1994-01-26	THE McLEAN HOSPITAL CORPORATION	Prophylactic and therapeutic treatment of Alzheimer's disease
US5607831A (en) *	1993-03-25	1997-03-04	The United States Of America As Represented By The Department Of Health And Human Services	In vitro methods for assessing the susceptibility of HIV-1-infected individuals to cysteine protease-mediated activation-induced programmed cell death

1994
- 1994-05-31 FR FR9406583A patent/FR2720277B1/fr not_active Expired - Lifetime
1995
- 1995-05-22 AU AU26206/95A patent/AU714209B2/en not_active Ceased
- 1995-05-22 JP JP8500420A patent/JPH10500978A/ja active Pending
- 1995-05-22 EP EP95920973A patent/EP0763121A1/fr not_active Withdrawn
- 1995-05-22 WO PCT/FR1995/000670 patent/WO1995033060A1/fr not_active Application Discontinuation
- 1995-05-22 CA CA2190293A patent/CA2190293C/fr not_active Expired - Fee Related
1996
- 1996-11-11 NO NO19964772A patent/NO321411B1/no not_active IP Right Cessation
- 1996-11-29 FI FI964783A patent/FI120501B/fi not_active IP Right Cessation

Also Published As

Publication number	Publication date
FI120501B (fi)	2009-11-13
FI964783A0 (fi)	1996-11-29
FR2720277A1 (fr)	1995-12-01
EP0763121A1 (fr)	1997-03-19
CA2190293C (fr)	2011-06-28
AU714209B2 (en)	1999-12-23
WO1995033060A1 (fr)	1995-12-07
CA2190293A1 (fr)	1995-12-07
NO321411B1 (no)	2006-05-08
FI964783L (fi)	1996-11-29
FR2720277B1 (fr)	1996-07-12
NO964772L (no)	1996-11-11
NO964772D0 (no)	1996-11-11
AU2620695A (en)	1995-12-21

Publication	Publication Date	Title
Stein et al.	1987	Repression of insulin gene expression by adenovirus type 5 Ela proteins
KR100379569B1 (ko)	2004-03-06	개기원의아데노바이러스벡터및유전자치료에서이의사용방법
JP4334174B2 (ja)	2009-09-30	腫瘍崩壊性アデノウイルス
ES2264123T3 (es)	2006-12-16	Adenovirus recombinantes defectivos para la terapia genica de tumores.
EP0998307B1 (en)	2006-10-11	METHOD FOR TREATING VASCULAR PROLIFERATIVE DISEASES WITH p27 AND FUSIONS THEREOF
AU710727B2 (en)	1999-09-30	Adenovirus comprising a gene coding for glutathion peroxidase
JPH10505485A (ja)	1998-06-02	スーパーオキシドジスムターゼをコードする遺伝子を含むアデノウイルス
Mannervik et al.	1999	Adenovirus E4 open reading frame 4-induced dephosphorylation inhibits E1A activation of the E2 promoter and E2F-1-mediated transactivation independently of the retinoblastoma tumor suppressor protein
EP0729516A1 (fr)	1996-09-04	Adenovirus recombinants pour la therapie genique des cancers
JPH10500978A (ja)	1998-01-27	ｐ５３タンパク質の調節による腫瘍の治療方法
US20050048466A1 (en)	2005-03-03	Specific proliferation in tumour cell which can express antioncogene with high efficiency and the use of it
Agarwal et al.	1995	Comparison of Gene Expression in Normal and Growth Hormone Receptor-Deficient Dwarf Chickens Reveals a Novel Growth Hormone-Regulated Gene
CN107073078B (zh)	2021-07-06	利用肝细胞生长因子和基质细胞衍生因子1α的用于预防或治疗外周动脉疾病的组合物
Randrianarison et al.	2001	BRCA1 carries tumor suppressor activity distinct from that of p53 and p21
US7837991B2 (en)	2010-11-23	Method of cancer treatment by p53 protein control
JP2002507384A (ja)	2002-03-12	アデノウイルスベクターの製造方法、それによって製造したベクターおよびその使用
KR100403893B1 (ko)	2004-02-19	글루타메이트 디 카르복실라제(gad) 활성을 암호화하는 재조합바이러스
JPH10506289A (ja)	1998-06-23	２の治療的遺伝子：自殺性および免疫刺激性遺伝子を含むアデノウイルス
JPH09509059A (ja)	1997-09-16	アルツハイマー病の動物モデル、調製方法および使用
MXPA96005522A (en)	1998-02-01	Method for the treatment of cancer through the control of protein
JP2002506078A (ja)	2002-02-26	プラスミノーゲン関連遺伝子ｂポリペプチド
AU747287B2 (en)	2002-05-16	Adenovirus including a gene coding for a superoxide dismutase
RU2021125067A (ru)	2023-03-06	Полинуклеотиды
Gianfranceschi et al.	1980	Inhibition of exogenous mRNA translation in a cell-free system by chromatin peptides from calf thymus
JP2577091C (fi)	1999-01-13

Legal Events

Date	Code	Title	Description
2006-02-28	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060228
2006-06-15	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060529
2006-07-10	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060710
2006-09-14	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060828
2006-11-07	A02	Decision of refusal	Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20061107
2007-02-06	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070205